Satellos Bioscience Completes Enrollment For BASECAMP, Phase 2 Clinical Trial Evaluating Forazapadin For Treatment Of Duchenne Muscular Dystrophy In Ambulatory Boys 7 To 10 Years Of Age
Satellos Bioscience Inc. (NASDAQ:MSLE, TSX:MSCL), a clinical-stage drug development company developing life-improving medicines to treat degenerative muscle diseases, today announced that enrollment has been completed
Share
Why It Matters
Satellos finished signing up patients for a medicine test. This shows the company is moving forward with its plan to help kids with muscle disease.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.